pSivida Corp (PSDV)

1.77
0.00 (0.00)
NASDAQ : Health Care
Prev Close 1.77
Open 1.79
Day Low/High 1.76 / 1.80
52 Wk Low/High 2.37 / 5.81
Volume 258.02K
Avg Volume 741.60K
Exchange NASDAQ
Shares Outstanding 39.36M
Market Cap 72.02M
EPS -0.70
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week of January 2018 Options Trading For pSivida (PSDV)

Investors in pSivida Corp saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

PSivida Announces 13 New Patents Issued Or Allowed

PSivida Announces 13 New Patents Issued Or Allowed

U.S. and foreign patents for bioerodible Medidur™, new smaller needle Medidur injector and Tethadur™

Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle

Primary Endpoint Met In PSivida's Utilization Study Of New Medidur™ Inserter With Smaller Diameter Needle

Results to Form Part of Planned Applications for Marketing Approvals in EU and US

PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer

PSivida Names Dario Paggiarino, M.D. As Chief Medical Officer

Industry Veteran Brings Over 25 Years of Pharmaceutical and Drug Development Experience

PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)

PSivida's Medidur™ Maintains Same High Statistical Significance In Primary Endpoint Through 12 Months In First Phase 3 Trial (p Less Than 0.00000001)

Incremental Risk of Elevated IOP Relative to Control Decreases Through Last Follow-up Visit

Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy

Data Shows PSivida's Tethadur™ Provides Prolonged, Sustained Release Of Avastin® With High Drug Efficacy

Data Presented at 2016 Annual Meeting & Exposition of the Controlled Release Society

PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility

PSivida Corp. Announces Plan To Consolidate All Research And Development In Current U.S. Facility

Plan to Facilitate Product Development and Reduce Operating Expenses

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Investigator-Sponsored Phase 2 Study Results Show PSivida's Medidur® Fully Controlled Uveitis For Two Years With No Recurrence Of Disease While Visual Acuity Continued To Improve

Study Results Showing No Recurrence of Disease and Statistically Significant Improvement in Visual Acuity to be Published in Ophthalmology